A detailed history of Brewin Dolphin Wealth Management LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Brewin Dolphin Wealth Management LTD holds 602 shares of VRTX stock, worth $284,625. This represents 0.02% of its overall portfolio holdings.

Number of Shares
602
Previous 301 100.0%
Holding current value
$284,625
Previous $79,000 107.59%
% of portfolio
0.02%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Nov 14, 2022

BUY
$234.96 - $292.55 $70,722 - $88,057
301 Added 100.0%
602 $164,000
Q4 2021

Nov 14, 2022

BUY
$177.01 - $223.45 $53,280 - $67,258
301 New
301 $66,000
Q1 2021

Nov 09, 2023

BUY
$207.02 - $241.31 $41,404 - $48,262
200 Added 198.02%
301 $64.7 Million
Q4 2020

Nov 09, 2023

BUY
$207.01 - $276.09 $13,662 - $18,221
66 Added 188.57%
101 $23.9 Million
Q3 2020

Nov 09, 2023

SELL
$255.65 - $303.1 $144,953 - $171,857
-567 Reduced 94.19%
35 $9.52 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Brewin Dolphin Wealth Management LTD Portfolio

Follow Brewin Dolphin Wealth Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brewin Dolphin Wealth Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Brewin Dolphin Wealth Management LTD with notifications on news.